NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,068 | -30.6% | 10,550 | -15.2% | 0.00% | -100.0% |
| Q1 2023 | $8,740 | -68.9% | 12,434 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $28,101 | -40.2% | 12,434 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $47,000 | -70.1% | 12,434 | -57.4% | 0.00% | -60.0% |
| Q1 2022 | $157,000 | -91.1% | 29,188 | -73.6% | 0.01% | -91.0% |
| Q4 2021 | $1,756,000 | +329.3% | 110,437 | +401.4% | 0.11% | +296.4% |
| Q3 2021 | $409,000 | +24.7% | 22,024 | +26.9% | 0.03% | +27.3% |
| Q2 2021 | $328,000 | +35.5% | 17,361 | +47.2% | 0.02% | +29.4% |
| Q1 2021 | $242,000 | -40.2% | 11,792 | +256.3% | 0.02% | -55.3% |
| Q2 2020 | $405,000 | -24.7% | 3,310 | -76.7% | 0.04% | -33.3% |
| Q4 2019 | $538,000 | +147.9% | 14,177 | +19.1% | 0.06% | +128.0% |
| Q3 2019 | $217,000 | – | 11,904 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |